KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2016 - 2025)

Rigel Pharmaceuticals has reported Income from Continuing Operations over the past 16 years, most recently at 268065000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 268065000.0 for Q4 2025, up 1769.22% from a year ago — trailing twelve months through Dec 2025 was 366989000.0 (up 1998.88% YoY), and the annual figure for FY2025 was 367024000.0, up 1999.08%.
  • Income from Continuing Operations for Q4 2025 was 268065000.0 at Rigel Pharmaceuticals, up from 27900000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for RIGL hit a ceiling of 268065000.0 in Q4 2025 and a floor of 27445000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 5 years was 3361000.0 (2023), compared with a mean of 14144750.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 169.48% in 2022 and later surged 5887.67% in 2025.
  • Rigel Pharmaceuticals' Income from Continuing Operations stood at 22636000.0 in 2021, then soared by 106.19% to 1401000.0 in 2022, then tumbled by 47.39% to 737000.0 in 2023, then skyrocketed by 1845.86% to 14341000.0 in 2024, then soared by 1769.22% to 268065000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 268065000.0 (Q4 2025), 27900000.0 (Q3 2025), and 59613000.0 (Q2 2025) per Business Quant data.